Alnylam Pharmaceuticals has pocketed around $1.2 million after Novartis fully exercised its right to purchase an additional 65,922 unregistered shares of Alnylam's common stock, pursuant to the companies' 2005 drug-discovery and -development deal, Novartis said this week.

Novartis, which Alnylam lists as its second biggest shareholder, said its decision to purchase the additional stock, for which it paid $17.50 per share, allows it to maintain its current 13.4 percent stake in Alnylam.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: International Wheat Genome Sequencing Consortium publishes the bread wheat cultivar Chinese Spring reference genome, and more.

At his FDA Law Blog, Jeffrey Gibbs discusses FDA's technical assistance for the draft Diagnostic Accuracy and Innovation Act.

The New York Times reports that genetic testing has uncovered unfaithful penguins at a Utah aquarium.

Cancer researcher loses funding under new Wellcome Trust anti-bullying policies, the Guardian reports.